ARDX (ardelyx.com) Market Value to Book Value Ratio

Official company branding of Ardelyx Inc (ARDX)

The visualized price action for Ardelyx, Inc. (ARDX) demonstrates the dynamics of an asset with a value of 4.96. Ardelyx, Inc. (ARDX) specializes in therapies for nephrological pathologies and IBS, generating long-term cash flows through integration into treatment protocols. The business is currently monetizing its breakthrough developments, Xphozah and Ibsrela, while expanding its clinical research base. A unique phosphorus-lowering method provides a competitive advantage, granting the company access to the dialysis market.

ARDX Ardelyx Corp: Market Value to Book Value in the range 07/04/2022 - 10/28/2026

Financial and market metric breakdowns for Ardelyx Inc (ARDX)

- price and consensus price forecast:
Stock Quotes Ardelyx, Inc.|ARDX - Broker Consensus Forecast
- market capitalization data:
Market Value Ardelyx Pharma|ARDX - Full Business Value
- book capitalization data:
Book Value per Share Ardelyx|ARDX - Accounting Value of Company|Market Capitalization to Book Value Ratio ardelyx.com|ARDX - Company Total Assets
- debt and liquidity data:
Debt to Equity Ardelyx, Inc.|ARDX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ardelyx Pharma|ARDX - Company Total Debt|Debts to Book Capitalization Ardelyx Pharma
Initial company analysis:Ardelyx, Inc. - ARDX
Original product of Ardelyx Pharma

This indicator measures the control premium of the business by comparing the company's market value with its net assets to identify capital overvaluation or undervaluation. Analyzing the price-to-book ratio allows for an assessment of how the market values the unique mechanism of action of Ardelyx (ARDX) drugs as it competes with pharmaceutical behemoths for nephrologist loyalty and market share.

Main competitors

Market Cap to Net Assets Ratio Travere Therapeutics|PROK (prokidney.com) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio Akebia Therapeutics, Inc. AKBA|Market Capitalization to Net Assets Cara Therapeutics, Inc.|DiaMedica Pharma (DMAC) - Market Capitalization to Book Value Ratio|Market Value to Book Value Unicycive Therapeutics, Inc (UNCY)|Market Capitalization to Book Value Ratio RMTI (Rockwell Medical, Inc.)|cadrenal.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Conduit Pharmaceuticals Inc. (CDT)|CALT: Market Value to Book Value|RNLX (Renalytix) - Market Value to Book Value Ratio|ZyVersa Therapeutics, Inc. (ZVSA) - Market Cap to Net Assets Ratio